AdultPediatricDosage Forms & Strengths tablet, extended-release 25mg (Myrbetriq, generic) 50mg (Myrbetriq, generic) Overactive Bladder Monotherapy Indicated for overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency 25 mg PO qDay 25 mg dose is typically effective within 8 weeks May increase to 50 mg PO qDay based on individual efficacy and tolerability Combination with muscarinic antagonist Indicated in combination with the muscarinic antagonist solifenacin succinate for treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency Combination regimen: 25 mg PO qDay plus solifenacin succinate 5 mg PO qDay May increase mirabegron to 50 mg PO qDay after 4-8 weeks based on individual efficacy and tolerability Dosage Modifications Renal impairment Mild-to-moderate (eGFR ≥30 mL/min/1.73 m2): No dosage adjustment required Severe (eGFR 15-29 mL/min/1.73 m2): Not to exceed 25 mg/day eGFR <15mL/min/1.73 m2 or on dialysis: Not recommended Hepatic impairment Mild (Child-Pugh A): No dosage adjustment required Moderate (Child-Pugh B): Not to exceed 25 mg/day for either starting or maximum dose Severe (Child Pugh C): Not recommended Dosing Considerations Granules and tablets are 2 different products and are not substitutable on a milligram-per-milligram basis Recommended dosage for granules in adults has not been determined Dosage Forms & Strengths tablet, extended-release 25mg (Myrbetriq, generic) 50mg (Myrbetriq, generic) granules for extended-release oral suspension 8mg/mL after reconstitution (Myrbetriq Granules) Neurogenic Detrusor Overactivity Indicated for neurogenic detrusor overactivity (NDO) in children aged 3 years and older <3 years: Safety and efficacy not established Aged ≥3 years, weight <35 kg Granules for oral suspension 11 kg to <22 kg: 24 mg (3 mL) PO qDay initially; may increase to maximum of 48 mg/day (6 mL) 22 kg to <35 kg: 32 mg (4 mL) PO qDay initially; may increase to maximum of 64 mg/day (8 mL) Aged ≥3 years, weight ≥35 kg Tablets: 25 mg PO qDay initially; may increase to maximum of 50 mg/day after 4-8 weeks Granules for oral suspension: 48 mg (6 mL) PO qDay initially; may increase to maximum of 80 mg/day (10 mL) after 4-8 weeks Dosage Modifications Renal impairment <35 kg Granules for oral suspension eGFR >30 mL/min/1.73 m2: No dosage adjustment required eGFR 15-29 mL/min/1.73 m2 11 kg to <22 kg: Not to exceed 24 mg (3 mL) for either starting or maximum dose 22 kg to <35 kg: Not to exceed 32 mg (4 mL) for either starting or maximum dose eGFR <15 mL/min/1.73 m2 or on dialysis: Not recommended Renal impairment ≥35 kg Granules for oral suspension eGFR ≥30 mL/min/1.73 m2: No dosage adjustment required eGFR 15-29 mL/min/1.73 m2: 48 mg (6 mL) for either starting or maximum dose eGFR <15 mL/min/1.73 m2 or on dialysis: Not recommended Tablets eGFR ≥30 mL/min/1.73 m2: No dosage adjustment required eGFR 15-29 mL/min/1.73 m2: 25 mg for either starting or maximum dose eGFR <15 mL/min/1.73 m2 or on dialysis: Not recommended Hepatic impairment <35 kg Granules for oral suspension Mild (Child-Pugh A): No dosage adjustment required Moderate (Child-Pugh B) 11 kg to <22 kg: Not to exceed 24 mg (3 mL) for either starting or maximum dose 22 kg to <35 kg: Not to exceed 32 mg (4 mL) for either starting or maximum dose Severe (Child-Pugh C): Not recommended Hepatic impairment ≥35 kg Granules for oral suspension Mild (Child-Pugh A): No dosage adjustment required Moderate (Child-Pugh B): Not to exceed 48 mg (6 mL) for either starting or maximum dose Severe (Child Pugh C): Not recommended Tablets Mild (Child-Pugh A): No dosage adjustment required Moderate (Child-Pugh B): Not to exceed 25 mg/day for either starting or maximum dose Severe (Child Pugh C): Not recommended Dosing Considerations Granules and tablets are 2 different products and are not substitutable on a milligram-per-milligram basis Select recommended product based on the indication and child’s weight Do not combine tablets and granules to achieve a total dose Recommended dosage for granules in adults has not been determined Interaction CheckerEnter a drug name and mirabegronNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (0)Serious - Use Alternative (2)metoclopramide intranasalmirabegron will increase the level or effect of metoclopramide intranasal by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Concurrent use of metoclopramide intranasal and strong CYP2D6 inhibitors is not recommended since the metoclopramide intranasal dose cannot be adjusted.ozanimodozanimod increases toxicity of mirabegron by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Because the active metabolite of ozanimod inhibits MAO-B in vitro, there is a potential for serious adverse reactions, including hypertensive crisis. Therefore, coadministration of ozanimod with drugs that can increase norepinephrine or serotonin is not recommended. Monitor for hypertension with concomitant use.Monitor Closely (60)amitriptylinemirabegron will increase the level or effect of amitriptyline by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.amoxapinemirabegron will increase the level or effect of amoxapine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.aripiprazolemirabegron will increase the level or effect of aripiprazole by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.atomoxetinemirabegron will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.betaxololmirabegron will increase the level or effect of betaxolol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.captoprilmirabegron will increase the level or effect of captopril by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.carvedilolmirabegron will increase the level or effect of carvedilol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.chloroquinemirabegron will increase the level or effect of chloroquine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.chlorpromazinemirabegron will increase the level or effect of chlorpromazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.cinacalcetmirabegron will increase the level or effect of cinacalcet by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.citaloprammirabegron will increase the level or effect of citalopram by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.clomipraminemirabegron will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.codeinemirabegron will increase the level or effect of codeine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.desipraminemirabegron will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.deutetrabenazinemirabegron will increase the level or effect of deutetrabenazine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Strong CYP2D6 inhibitors increase the systemic exposure to the active dihydro-metabolites of deutetrabenazine by approximately 3-fold. Do not exceed 18 mg/dose and 36 mg/day of deutetrabenazine if coadministered with strong CYP2D6 inhibitors.dextroamphetamine transdermalmirabegron will increase the level or effect of dextroamphetamine transdermal by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during dextroamphetamine initiation and after a dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and CYP2D6 inhibitor.digoxinmirabegron will increase the level or effect of digoxin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.doxepinmirabegron will increase the level or effect of doxepin by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.doxepin creammirabegron will increase the level or effect of doxepin cream by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.doxorubicinmirabegron will increase the level or effect of doxorubicin by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.doxorubicin liposomalmirabegron will increase the level or effect of doxorubicin liposomal by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.duloxetinemirabegron will increase the level or effect of duloxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.flecainidemirabegron will increase the level or effect of flecainide by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.fluoxetinemirabegron will increase the level or effect of fluoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.fluphenazinemirabegron will increase the level or effect of fluphenazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.fluvoxaminemirabegron will increase the level or effect of fluvoxamine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.haloperidolmirabegron will increase the level or effect of haloperidol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.iloperidonemirabegron will increase the level or effect of iloperidone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.imipraminemirabegron will increase the level or effect of imipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.lofexidinemirabegron will increase the level or effect of lofexidine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Concomitant use of lofexidine with strong CYP2D6 inhibitors may increase lofexidine plasma levels. Monitor for symptoms of orthostasis and bradycardia if coadministered with a CYP2D6 inhibitor. Consider lofexidine dose reduction.maprotilinemirabegron will increase the level or effect of maprotiline by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.metaxalonemirabegron will increase the level or effect of metaxalone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.methamphetaminemirabegron will increase the level or effect of methamphetamine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.metoprololmirabegron will increase the level or effect of metoprolol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.mirtazapinemirabegron will increase the level or effect of mirtazapine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.nebivololmirabegron will increase the level or effect of nebivolol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.nefazodonemirabegron will increase the level or effect of nefazodone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.nortriptylinemirabegron will increase the level or effect of nortriptyline by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.oliceridinemirabegron will increase the level or effect of oliceridine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. If concomitant use is necessary, may require less frequent oliceridine dosing. Closely monitor for respiratory depression and sedation and titrate subsequent doses accordingly. If inhibitor is discontinued, consider increase oliceridine dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal. paroxetinemirabegron will increase the level or effect of paroxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.perphenazinemirabegron will increase the level or effect of perphenazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.pindololmirabegron will increase the level or effect of pindolol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.pitolisantmirabegron will increase the level or effect of pitolisant by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. If coadministered with strong CYP2D6 inhibitors, initiate pitolisant at 8.9 mg/day and increase after 7 days to maximum of 17.8 mg/day. For patients currently taking pitolisant, reduce pitolisant dose by half upon initiating strong CYP2D6 inhibitors.procainamidemirabegron will increase the level or effect of procainamide by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.promethazinemirabegron will increase the level or effect of promethazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.propafenonemirabegron will increase the level or effect of propafenone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.propranololmirabegron will increase the level or effect of propranolol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.protriptylinemirabegron will increase the level or effect of protriptyline by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.risperidonemirabegron will increase the level or effect of risperidone by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.ritonavirmirabegron will increase the level or effect of ritonavir by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.sertralinemirabegron will increase the level or effect of sertraline by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.solifenacinmirabegron increases toxicity of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor patients for signs/symptoms of urinary retention.tamoxifenmirabegron will decrease the level or effect of tamoxifen by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.thioridazinemirabegron will increase the level or effect of thioridazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.timololmirabegron will increase the level or effect of timolol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.timolol ophthalmicmirabegron will increase the level or effect of timolol ophthalmic by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.tolterodinemirabegron will increase the level or effect of tolterodine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.tramadolmirabegron will increase the level or effect of tramadol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.trimipraminemirabegron will increase the level or effect of trimipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.venlafaxinemirabegron will increase the level or effect of venlafaxine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.Minor (1)benazeprilmirabegron decreases effects of benazepril by pharmacodynamic antagonism. Minor/Significance Unknown. Monitor blood pressure.amitriptylineMonitor Closely (1)mirabegron will increase the level or effect of amitriptyline by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.amoxapineMonitor Closely (1)mirabegron will increase the level or effect of amoxapine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.aripiprazoleMonitor Closely (1)mirabegron will increase the level or effect of aripiprazole by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.atomoxetineMonitor Closely (1)mirabegron will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.benazeprilMinor (1)mirabegron decreases effects of benazepril by pharmacodynamic antagonism. Minor/Significance Unknown. Monitor blood pressure.betaxololMonitor Closely (1)mirabegron will increase the level or effect of betaxolol by affecting hepatic enzyme CYP2D6 metabolism.